info@cytospector.com
Cytospector
  • Home
  • Expertise
  • High-content assays
    • Standardized phenotypic assay
    • Alzheimer´s disease assay
    • Schizophrenia assay
  • Assay development
  • About us
  • Contact
  • Home
  • Expertise
  • High-content assays
    • Standardized phenotypic assay
    • Alzheimer´s disease assay
    • Schizophrenia assay
  • Assay development
  • About us
  • Contact

Alzheimer´s disease assay

Cytospector’s assay for Alzheimer’s disease (AD) evaluates the effect of selected compounds or genes on Aβ-induced synaptic toxicity. This assay can be used to identify or validate novel therapeutics or targets for AD.

Increased levels of Aβ, and the formation of toxic Aβ oligomers in the brain, are early causative events in the development of AD. Aβ-induced synaptic toxicity is regarded as the primary disease mechanism that underlies reduced cognitive function, and therefore constitutes an important drug target in AD research.

Overexpression of APP, which leads to increased extracellular Aβ levels, consistently decreases the number and function of synapses. Our Alzheimer’s disease assay evaluates the potency of selected experimental manipulations to rescue this synaptic phenotype.

STANDARD PHENOTYPIC ASSAY

based on a variety of cellular and synaptic parameters

Read More

ALZHEIMER´S DISEASE ASSAY

For compound of genetic screens

Read More

SCHIZOPHRENIA ASSAY

For compound or genetics screens

Read More

CYTOSPECTOR

  • Home
  • Expertise
  • High-content assays
  • Standardized phenotypic assay
  • Alzheimer´s disease assay
  • Assay development
  • About us
  • Contact

CONTACT

Cytospector
PO Box 71033
1008 BA Amsterdam
The Netherlands

info@cytospector.com

© Copyright 2015 •Cytospector •